本文概括分析了近些年来,针对延迟性哀伤障碍(PGD)的研究进展,主要涉及诊断标准、鉴别要点、易感和影响因素以及可能的发病机制。认为目前ICD-11或DSM-5-TR相应的PGD诊断标准,还需要考虑文化差异、跨文化因素,甚至宗教信仰等方面的影响,以便今后制定出具有较广泛适应性的、可操作性的诊断标准。This article summarizes and analyzes the research progress on postpone grief disorder in recent years, mainly involving diagnostic criteria, differentiation points, susceptibility and influencing factors, as well as possible pathogenesis. It is believed that the current diagnostic criteria for PGD corresponding to ICD-11 or DSM-5-TR still need to consider the influence of cultural differences, cross-cultural factors, and even religious beliefs, in order to develop diagnostic criteria with broad applicability and operability in the future.
皮肌炎(dermatomyositis, DM)是一种主要累及骨骼肌和皮肤的自身免疫性疾病,常伴有特征性皮肤表现,继发或并发精神病性症状为临床少见。现报道一例DM继发精神病症状,在应用糖皮质激素基础上,联合小剂量抗精神病药物,获得良好效果的患者,以提高临床医生对DM合并精神症状的认识水平。Dermatomyositis is an autoimmune disease that primarily affects skeletal muscle and skin, often accompanied by characteristic skin damage manifestations. Secondary or concurrent psychiatric symptoms are clinically rare. Now we report a patient with secondary psychiatric symptoms, who achieved good results in combination with low-dose antipsychotic drugs on the basis of glucocorticoids. The purpose is to improve the clinical doctors’ recognition level on DM combined with psychiatric symptoms.
本文介绍一种在2020年被美国FDA批准用于临床精神分裂症的新型抗精神分裂症药物:SEP-363856。从该药物的药代动力学、受体作用机制、临床运用情况以及安全性和不良反应等方面作了总结。结论:SEP-363856治疗精神分裂症的阴、阳性症状均有效,且安全性、耐受性好,需要进一步扩大样本研究。The article introduces a novel antipsychotic drug, SEP-363856, approved by US FDA for clinical use in schizophrenia in 2020. A summary was made on the pharmacokinetics, receptor mechanism of action, clinical application, safety, and adverse reactions of the drug. Conclusion: SEP-363856 is effective in treating both negative and positive symptoms of schizophrenia and is safe and well tolerated. Further expansion of sample research is needed.
暂无评论